AstraZeneca bought Dogma Therapeutics for their promising pre clinical cholesterol lowering drug in same class as NYR in sept 2020. PSK9i
AZ have Crestor one of the largest selling statins on the market.
will AZ buy NYR too? highly likely. then they will have all bases covered on this "holy grail" of an oral anti PSK9i which is preferable to exiting injectables only.
or maybe Pfizer who have Lipitor will want a piece of the PSK9i small molecule class or be left behind.
to me it seems the big boys AZ (as they have already shown) or Pfizer will be take NYRs PSK9i project. it's just a question of who first ? or bidding war as more data comes out.
NYR Price at posting:
44.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)